$CRDF
Cardiff Oncology, Inc. Stock $crdf

$crdf Overview Financials Valuation SEC Filings Company Website

2016 Q2 Form 10-Q Financial Statement

#000162828016018502 Filed on August 04, 2016

Income Statement

Concept	2016 Q2	2015 Q4	2015 Q2
Revenue	$104.0K	$79.00K	$49.00K
YoY Change	112.24%	41.07%	-12.5%
Cost Of Revenue	$409.5K	$200.0K	$80.03K
YoY Change	411.64%	900.0%
Gross Profit	-$305.5K	-$120.0K	-$31.03K
YoY Change	884.41%	-400.0%
Gross Profit Margin	-293.71%	-151.9%	-63.33%
Selling, General & Admin	$5.598M	$4.150M	$3.917M
YoY Change	42.9%	16.25%	106.18%
% of Gross Profit
Research & Development	$4.076M	$3.110M	$2.684M
YoY Change	51.87%	220.62%	91.73%
% of Gross Profit
Depreciation & Amortization	$330.0K	$130.0K	$80.00K
YoY Change	312.5%	116.67%	33.33%
% of Gross Profit
Operating Expenses	$10.08M	$7.463M	$6.682M
YoY Change	50.91%	63.66%	102.67%
Operating Profit	-$9.980M	-$7.583M	-$6.632M
YoY Change	50.48%	67.77%
Interest Expense	-$220.0K	$10.00K	-$3.560M
YoY Change	-93.82%	-105.56%	-264.81%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$10.00K	$9.179K
YoY Change	-100.0%	-50.0%
Pretax Income	-$10.20M	-$7.380M	-$10.18M
YoY Change	0.2%	57.69%	842.59%
Income Tax
% Of Pretax Income
Net Earnings	-$10.20M	-$7.380M	-$10.18M
YoY Change	0.22%	57.69%	842.6%
Net Earnings / Revenue	-9809.88%	-9341.77%	-20775.58%
Basic Earnings Per Share	-$0.34	-$0.25	-$0.41
Diluted Earnings Per Share	-$0.34	-$0.26	-$0.41
COMMON SHARES
Basic Shares Outstanding	29.96M shares	29.72M shares	24.59M shares
Diluted Shares Outstanding	29.96M shares	30.16M shares	24.59M shares

Balance Sheet

Concept	2016 Q2	2015 Q4	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$50.60M	$67.50M	$41.30M
YoY Change	22.52%	147.25%	19.02%
Cash & Equivalents	$22.58M	$67.49M	$41.29M
Short-Term Investments	$28.00M
Other Short-Term Assets	$900.0K	$800.0K	$500.0K
YoY Change	80.0%	100.0%	66.67%
Inventory
Prepaid Expenses
Receivables	$158.5K	$98.74K	$100.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$51.62M	$68.38M	$41.90M
YoY Change	23.2%	146.69%	19.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.732M	$2.691M	$1.400M
YoY Change	237.98%	220.16%	75.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$371.2K	$374.0K	$400.0K
YoY Change	-7.19%	11.08%	33.33%
Total Long-Term Assets	$5.103M	$3.065M	$1.700M
YoY Change	200.18%	160.35%	41.67%
TOTAL ASSETS
Total Short-Term Assets	$51.62M	$68.38M	$41.90M
Total Long-Term Assets	$5.103M	$3.065M	$1.700M
Total Assets	$56.72M	$71.45M	$43.60M
YoY Change	30.1%	147.24%	20.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.115M	$1.041M	$1.100M
YoY Change	1.39%	39.19%	175.0%
Accrued Expenses	$3.627M	$1.904M	$1.500M
YoY Change	141.8%	3.37%	-6.25%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$6.100M	$5.200M	$2.300M
YoY Change	165.22%	173.68%
Total Short-Term Liabilities	$10.89M	$8.201M	$5.000M
YoY Change	117.78%	82.73%	150.0%
LONG-TERM LIABILITIES
Long-Term Debt	$9.000M	$11.20M	$12.90M
YoY Change	-30.23%	-14.5%	-12.24%
Other Long-Term Liabilities	$1.519M	$0.00	$7.700M
YoY Change	-80.27%	-100.0%	250.0%
Total Long-Term Liabilities	$1.519M	$0.00	$20.60M
YoY Change	-92.63%	-100.0%	21.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.89M	$8.201M	$5.000M
Total Long-Term Liabilities	$1.519M	$0.00	$20.60M
Total Liabilities	$24.15M	$22.74M	$25.50M
YoY Change	-5.29%	10.69%	34.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$129.4M	-$108.9M
YoY Change		33.78%
Common Stock	$3.015K	$2.974K
YoY Change		57.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$32.57M	$48.70M	$18.10M
YoY Change
Total Liabilities & Shareholders Equity	$56.72M	$71.45M	$43.60M
YoY Change	30.1%	147.24%	20.44%

Cashflow Statement

Concept	2016 Q2	2015 Q4	2015 Q2
OPERATING ACTIVITIES
Net Income	-$10.20M	-$7.380M	-$10.18M
YoY Change	0.22%	57.69%	842.6%
Depreciation, Depletion And Amortization	$330.0K	$130.0K	$80.00K
YoY Change	312.5%	116.67%	33.33%
Cash From Operating Activities	-$8.070M	-$6.810M	-$5.450M
YoY Change	48.07%	75.97%	105.66%
INVESTING ACTIVITIES
Capital Expenditures	-$320.0K	-$980.0K	-$440.0K
YoY Change	-27.27%	716.67%	4300.0%
Acquisitions
YoY Change
Other Investing Activities	-$27.95M	$10.00K
YoY Change		-83.33%
Cash From Investing Activities	-$28.27M	-$970.0K	-$440.0K
YoY Change	6325.0%	1516.67%	4300.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.060M	1.130M	3.190M
YoY Change	-133.23%	1783.33%	-77.95%
NET CHANGE
Cash From Operating Activities	-8.070M	-6.810M	-5.450M
Cash From Investing Activities	-28.27M	-970.0K	-440.0K
Cash From Financing Activities	-1.060M	1.130M	3.190M
Net Change In Cash	-37.40M	-6.650M	-2.700M
YoY Change	1285.19%	71.83%	-122.86%
FREE CASH FLOW
Cash From Operating Activities	-$8.070M	-$6.810M	-$5.450M
Capital Expenditures	-$320.0K	-$980.0K	-$440.0K
Free Cash Flow	-$7.750M	-$5.830M	-$5.010M
YoY Change	54.69%	55.47%	89.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Period End Date DocumentPeriodEndDate	2016-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001213037
CY2016Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30147514	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	trov	Share Based Compensation Number Of Options Issued Over Stock Option Authorized ShareBasedCompensationNumberOfOptionsIssuedOverStockOptionAuthorized	996000	shares
	trov	Adjustments To Additional Paid In Capital Warrants Reclassified Amount AdjustmentsToAdditionalPaidInCapitalWarrantsReclassifiedAmount	0	USD
CY2016Q2	trov	Area Of Land After Expansion AreaOfLandAfterExpansion	26100	sqft
	trov	Class Of Warrant Or Right Number Exercised ClassOfWarrantOrRightNumberExercised	50000	shares
CY2014	trov	Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights	P2Y6M
	trov	Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights	P2Y22D
CY2015Q4	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	3.86
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Trovagene, Inc.
CY2015Q2	trov	Adjustment For Change In Unrealized Gain Loss On Derivatives AdjustmentForChangeInUnrealizedGainLossOnDerivatives	0	USD
	trov	Adjustment For Change In Unrealized Gain Loss On Derivatives AdjustmentForChangeInUnrealizedGainLossOnDerivatives	0	USD
CY2016Q2	trov	Adjustment For Change In Unrealized Gain Loss On Derivatives AdjustmentForChangeInUnrealizedGainLossOnDerivatives	0	USD
	trov	Adjustment For Change In Unrealized Gain Loss On Derivatives AdjustmentForChangeInUnrealizedGainLossOnDerivatives	-533750	USD
	trov	Adjustments To Additional Paid In Capital Warrants Reclassified Amount AdjustmentsToAdditionalPaidInCapitalWarrantsReclassifiedAmount	-435365	USD
CY2016Q2	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	3.82
	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised	8.00
CY2015Q2	trov	Diagnostic Service Revenue DiagnosticServiceRevenue	2520	USD
	trov	Diagnostic Service Revenue DiagnosticServiceRevenue	4686	USD
CY2016Q2	trov	Diagnostic Service Revenue DiagnosticServiceRevenue	23962	USD
	trov	Diagnostic Service Revenue DiagnosticServiceRevenue	31580	USD
	trov	Leaseholdimprovementspaidforbylessor Leaseholdimprovementspaidforbylessor	0	USD
	trov	Leaseholdimprovementspaidforbylessor Leaseholdimprovementspaidforbylessor	1860000	USD
CY2015Q4	trov	Operating Lease Monthly Rent OperatingLeaseMonthlyRent	3100	USD
CY2016Q2	trov	Operating Lease Monthly Rent OperatingLeaseMonthlyRent	68000	USD
	trov	Operating Lease Monthly Rent OperatingLeaseMonthlyRent	60000	USD
	trov	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	12120	USD
	trov	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	12120	USD
CY2015Q2	trov	Totalcomprehensiveincomelossnetoftax Totalcomprehensiveincomelossnetoftax	-10180034	USD
	trov	Totalcomprehensiveincomelossnetoftax Totalcomprehensiveincomelossnetoftax	-17354415	USD
CY2016Q2	trov	Totalcomprehensiveincomelossnetoftax Totalcomprehensiveincomelossnetoftax	-10198291	USD
	trov	Totalcomprehensiveincomelossnetoftax Totalcomprehensiveincomelossnetoftax	-20461460	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1040868	USD
CY2016Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1115340	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	98736	USD
CY2016Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	158537	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-27481	USD
	us-gaap	Accretion Of Discount AccretionOfDiscount	57026	USD
	us-gaap	Accretion Of Discount AccretionOfDiscount	52641	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1934411	USD
CY2016Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3627005	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	854782	USD
CY2016Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1336877	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2016Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3336	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	157585498	USD
CY2016Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	161930622	USD
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1123446	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1835187	USD
CY2016Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1301913	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4113021	USD
CY2016Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	16033581	USD
CY2016Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	28004561	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	193066	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	181318	USD
	us-gaap	Amortization Of Deferred Leasing Fees AmortizationOfDeferredLeasingFees	0	USD
	us-gaap	Amortization Of Deferred Leasing Fees AmortizationOfDeferredLeasingFees	-66689	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11664964	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11113067	shares
CY2016Q2	us-gaap	Area Of Land AreaOfLand	22600	sqft
CY2015Q4	us-gaap	Area Of Land AreaOfLand	2300	sqft
CY2015Q4	us-gaap	Assets Assets	71445651	USD
CY2016Q2	us-gaap	Assets Assets	56722912	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	68381068	USD
CY2016Q2	us-gaap	Assets Current AssetsCurrent	51619931	USD
CY2016Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	9106	USD
CY2016Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3974	USD
CY2016Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	16038713	USD
CY2016Q2	us-gaap	Available For Sale Securities Short Term Investments Amortized Cost AvailableForSaleSecuritiesShortTermInvestmentsAmortizedCost	27999429	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27293798	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41293784	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67493047	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22578980	USD
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5533242	shares
CY2016Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5483242	shares
CY2016Q2	us-gaap	Commercial Paper CommercialPaper	11965848	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29737601	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30417305	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29737601	shares
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30417305	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	2974	USD
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	3015	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10186094	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17366535	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10204351	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20473580	USD
CY2015Q2	us-gaap	Cost Of Revenue CostOfRevenue	80030	USD
	us-gaap	Cost Of Revenue CostOfRevenue	256455	USD
CY2016Q2	us-gaap	Cost Of Revenue CostOfRevenue	409463	USD
	us-gaap	Cost Of Revenue CostOfRevenue	718734	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	152979	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3807501	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	489708	USD
CY2015Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	3297077	USD
CY2016Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2710451	USD
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.41
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.75
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.41
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.75
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.70
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-2473	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	3568	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2001516	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2468732	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6472979	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	800	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	4560	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	28234	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1481532	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	43023	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	59801	USD
	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	0	USD
	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	75300	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	26238	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2761	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	139149	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	88678	USD
CY2015Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2016Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	176596	shares
CY2015Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-381252	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-764721	USD
CY2016Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-274909	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-612529	USD
	us-gaap	Interest Paid InterestPaid	530250	USD
	us-gaap	Interest Paid InterestPaid	536727	USD
CY2015Q4	us-gaap	Lessee Leasing Arrangements Operating Leases Term Of Contract LesseeLeasingArrangementsOperatingLeasesTermOfContract	P3Y
CY2015Q4	us-gaap	Liabilities Liabilities	22744362	USD
CY2016Q2	us-gaap	Liabilities Liabilities	24150038	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	71445651	USD
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	56722912	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8201097	USD
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	10889089	USD
CY2016Q2	us-gaap	Line Of Credit LineOfCredit	1878312	USD
CY2016Q2	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	365227	USD
CY2015Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	11246188	USD
CY2016Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	9031389	USD
CY2015Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	5225818	USD
CY2016Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	6146744	USD
CY2016Q2	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	1528527	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	13999986	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-44914067	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	24865370	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-1295688	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-687965	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-28622478	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10177419	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-14993428	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-10180034	USD
	us-gaap	Net Income Loss NetIncomeLoss	-17354415	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-10202278	USD
	us-gaap	Net Income Loss NetIncomeLoss	-20464796	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10186094	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17366535	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10208338	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20476916	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-10186094	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-17366535	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-10208338	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-21010666	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	6681553	USD
	us-gaap	Operating Expenses OperatingExpenses	11656275	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	10083645	USD
	us-gaap	Operating Expenses OperatingExpenses	20662779	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6632207	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11479959	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9980245	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-20438893	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	374004	USD
CY2016Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	371243	USD
CY2015Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	0	USD
CY2016Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1145	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1796	USD
CY2015Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2016Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	3987	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	3336	USD
CY2015Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2016Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	5132	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	5132	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2016Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1519109	USD
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	9179	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	12747	USD
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2015Q2	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
CY2016Q2	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	31673	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	31673	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	0	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	27951611	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	687965	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	670867	USD
CY2015Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6060	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	12120	USD
CY2016Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6060	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	12120	USD
CY2015Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	606000	USD
CY2016Q2	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	606000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2016Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	60600	shares
CY2016Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	60600	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	60	USD
CY2016Q2	us-gaap	Preferred Stock Value PreferredStockValue	60	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	789285	USD
CY2016Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	877853	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	23816292	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	792251	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	564051	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	232144	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	485027	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3545361	USD
CY2016Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6068615	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2690579	USD
CY2016Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4731738	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2320083	USD
CY2015Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2684157	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	4881816	USD
CY2016Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	4076414	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	7284478	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-108887243	USD
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-129364159	USD
CY2015Q2	us-gaap	Royalty Revenue RoyaltyRevenue	46826	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	171630	USD
CY2016Q2	us-gaap	Sales Revenue Net SalesRevenueNet	103400	USD
CY2016Q2	us-gaap	Royalty Revenue RoyaltyRevenue	47765	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	160633	USD
CY2015Q2	us-gaap	Sales Revenue Net SalesRevenueNet	49346	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	176316	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	223886	USD
CY2015Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1915850	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2710503	USD
CY2016Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3129036	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6186588	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1835187	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4113021	USD
CY2015Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2016Q2	us-gaap	Short Term Investments ShortTermInvestments	28004561	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	48701289	USD
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	32572874	USD
CY2015Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-3175754	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-5122482	USD
CY2016Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	52876	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	586626	USD
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24592883	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23212963	shares
CY2016Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29958037	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30033207	shares
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24592883	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23212963	shares
CY2016Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29958037	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29856611	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-16-018502-index-headers.html	Edgar Link	pending
0001628280-16-018502-index.html	Edgar Link	pending
0001628280-16-018502.txt	Edgar Link	pending
0001628280-16-018502-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
trov-063016exhibit311.htm	Edgar Link	pending
trov-063016exhibit321.htm	Edgar Link	pending
trov-063016x10q.htm	Edgar Link	pending
trov-0630x16exhibit102.htm	Edgar Link	pending
trov-20160630.xml	Edgar Link	completed
trov-20160630.xsd	Edgar Link	pending
trov-20160630_cal.xml	Edgar Link	unprocessable
trov-20160630_def.xml	Edgar Link	unprocessable
trov-20160630_lab.xml	Edgar Link	unprocessable
trov-20160630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRDF
Cardiff Oncology, Inc. Stock $crdf

2016 Q2 Form 10-Q Financial Statement

#000162828016018502 Filed on August 04, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF Cardiff Oncology, Inc. Stock $crdf

2016 Q2 Form 10-Q Financial Statement

#000162828016018502 Filed on August 04, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF
Cardiff Oncology, Inc. Stock $crdf